MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural

Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Oncotarget 2018 April 17 [Link] Mönch D, Bode-Erdmann S, Kalla J, Sträter J, Schwänen C, Falkenstern-Ge R, Klumpp S, Friedel G, Ott G, Kalla C Abstract Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. Targeting aberrantly overexpressed kinases to cure MPM is a promising therapeutic strategy. Here, we examined […]

Comments Off on A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

Journal of Immunoassay & Immunochemistry 2018 May 14 [Link] Mlika M, Lamzibri O, Bacha S, Laabidi S, Haddouchi C, Mezni FE Abstract BACKGROUND: malignant pleural mesothelioma (MPM) is a rare tumor with a challenging diagnosis. Even if, clinical data are mandatory to suspect the diagnosis, the positive diagnosis is based on microscopic features. Morphologic features […]

Comments Off on How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

The Lancet. Respiratory Medicine. 2018 May 14 [Link] Calabrò L, Morra A, Giannarelli D, Amato G, D’Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, Di Giacomo AM, Maio M Abstract BACKGROUND: Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve […]

Comments Off on Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

Oncotarget 2018 April 24 [Link] Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, Gorgoulis VG, Kalomenidis I Abstract Malignant pleural mesothelioma is resistant to currently used treatment. Angiopoieitn-1 directly promotes mesothelioma cell growth in a Tie-2-dependent fashion. Angiopoietin/Tie-2 axis may thus be valid targets for therapeutic interventions against mesothelioma. […]

Comments Off on Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

Human Pathology 2018 May 12 [Link] Lee HE, Molina JR, Sukov WR, Roden AC, Yi ES Abstract Literature on BRCA1-associated protein 1 (BAP1) expression status in well-differentiated papillary mesothelioma (WDPM) is limited. In the present study, we examined the prevalence of BAP1 loss in WDPM by immunohistochemistry with clinical correlation, along with CDKN2A deletion status […]

Comments Off on BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Journal of Thoracic Oncology 2018 May 3 [Link] Burt BM, Richards WG, Lee HS, Bartel S, Dasilva MC, Gill RR, Jaklitsch MT, Johnson BE, Swanson SJ, Bueno R, Sugarbaker DJ Abstract INTRODUCTION: The primary objective of this single-institution Phase I clinical trial was to establish the maximum tolerated dose (MTD) of gemcitabine added to cisplatin […]

Comments Off on A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Journal of Thoracic Oncology May 9 2018 [Link] Armato SG, Nowak AK Abstract Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, interpretation, and reporting of clinical trials. The current de-facto standard for the assessment of mesothelioma tumor response, […]

Comments Off on Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Lung Cancer [Epub March 2018] [Link] Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C Abstract OBJECTIVES: Cisplatin-based chemotherapy is moderately active in malignant pleural mesothelioma (MPM) due to […]

Comments Off on Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis

Lung Cancer June 2018 [Link] Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Culligan MJ, Friedberg JS, Simone CB Abstract PURPOSE: This study of a large, contemporary national database evaluated postoperative outcomes and overall survival (OS) for malignant pleural mesothelioma (MPM) by facility volume. METHODS: The National Cancer Database was queried for newly-diagnosed […]

Comments Off on Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis

An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd/boron multimodal probes for MRI guided BNCT

Journal of controlled release 2018 May 3 [Link] Alberti D, Deagostino A, Toppino A, Protti N, Bortolussi S, Altieri S, Aime S, Crich SG Abstract The aim of this study is to develop an innovative imaging guided approach based on Boron Neutron Capture Therapy, for the treatment of mesothelioma, assisted by the quantification of the […]

Comments Off on An innovative therapeutic approach for malignant mesothelioma treatment based on the use of Gd/boron multimodal probes for MRI guided BNCT